ES2183937T3 - Inhibidores de la adhesion celular. - Google Patents
Inhibidores de la adhesion celular.Info
- Publication number
- ES2183937T3 ES2183937T3 ES96905316T ES96905316T ES2183937T3 ES 2183937 T3 ES2183937 T3 ES 2183937T3 ES 96905316 T ES96905316 T ES 96905316T ES 96905316 T ES96905316 T ES 96905316T ES 2183937 T3 ES2183937 T3 ES 2183937T3
- Authority
- ES
- Spain
- Prior art keywords
- compounds
- inhibitors
- cellular adhesion
- cell adhesion
- cellular
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000021164 cell adhesion Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 230000001413 cellular effect Effects 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 230000001404 mediated effect Effects 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/19—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and carboxyl groups, other than cyano groups, bound to the same saturated acyclic carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/38—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by doubly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/46—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylureas
- C07C275/48—Y being a hydrogen or a carbon atom
- C07C275/54—Y being a carbon atom of a six-membered aromatic ring, e.g. benzoylureas
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
- C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C317/50—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/55—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Abstract
LA PRESENTE INVENCION SE REFIERE A NUEVOS COMPUESTOS UTILES PARA LA INHIBICION Y PREVENCION DE LA ADHESION CELULAR Y PATOLOGIAS MEDIADAS POR LA ADHESION CELULAR, ASI COMO A FORMULACIONES FARMACEUTICAS QUE INCLUYEN ESTOS COMPUESTOS Y METODOS DE UTILIZACION DE LAS MISMAS PARA LA INHIBICION Y PREVENCION DE LA ADHESION CELULAR Y PATOLOGIAS MEDIADAS POR LA ADHESION CELULAR. LOS COMPUESTOS Y COMPOSICIONES FARMACEUTICAS DE LA INVENCION PUEDEN UTILIZARSE COMO AGENTES TERAPEUTICOS O PROFILACTICOS. SON PARTICULARMENTE ADECUADOS PARA EL TRATAMIENTO DE MUCHAS ENFERMEDADES INFLAMATORIAS Y AUTOINMUNES.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/376,372 US6306840B1 (en) | 1995-01-23 | 1995-01-23 | Cell adhesion inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2183937T3 true ES2183937T3 (es) | 2003-04-01 |
Family
ID=23484763
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES96905316T Expired - Lifetime ES2183937T3 (es) | 1995-01-23 | 1996-01-18 | Inhibidores de la adhesion celular. |
Country Status (29)
Country | Link |
---|---|
US (5) | US6306840B1 (es) |
EP (2) | EP1142867A2 (es) |
JP (2) | JP4129293B2 (es) |
KR (1) | KR100413328B1 (es) |
CN (1) | CN1192015C (es) |
AT (1) | ATE229498T1 (es) |
AU (1) | AU718926B2 (es) |
BG (1) | BG63383B1 (es) |
BR (1) | BR9606778A (es) |
CA (1) | CA2211181A1 (es) |
CZ (1) | CZ291556B6 (es) |
DE (1) | DE69625332T2 (es) |
DK (1) | DK0805796T3 (es) |
EA (2) | EA003320B1 (es) |
EE (1) | EE04111B1 (es) |
ES (1) | ES2183937T3 (es) |
FI (1) | FI973087A (es) |
HK (2) | HK1005241A1 (es) |
HU (1) | HU223350B1 (es) |
IL (1) | IL116846A (es) |
MX (1) | MX9705569A (es) |
NO (1) | NO320914B1 (es) |
NZ (1) | NZ336104A (es) |
PL (1) | PL187313B1 (es) |
PT (1) | PT805796E (es) |
RO (1) | RO119885B1 (es) |
SK (1) | SK283724B6 (es) |
TW (1) | TW500714B (es) |
WO (1) | WO1996022966A1 (es) |
Families Citing this family (195)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6306840B1 (en) * | 1995-01-23 | 2001-10-23 | Biogen, Inc. | Cell adhesion inhibitors |
US5849711A (en) * | 1995-06-06 | 1998-12-15 | Athena Neurosciences, Inc. | Cathepsin and methods and compositions for inhibition thereof |
JPH11506923A (ja) * | 1995-06-06 | 1999-06-22 | アセナ ニューロサイエンシーズ,インコーポレイテッド | 新しいカテプシンならびにその阻害のための方法および組成物 |
US6613508B1 (en) | 1996-01-23 | 2003-09-02 | Qiagen Genomics, Inc. | Methods and compositions for analyzing nucleic acid molecules utilizing sizing techniques |
US6312893B1 (en) | 1996-01-23 | 2001-11-06 | Qiagen Genomics, Inc. | Methods and compositions for determining the sequence of nucleic acid molecules |
US6027890A (en) * | 1996-01-23 | 2000-02-22 | Rapigene, Inc. | Methods and compositions for enhancing sensitivity in the analysis of biological-based assays |
US6686350B1 (en) | 1996-07-25 | 2004-02-03 | Biogen, Inc. | Cell adhesion inhibitors |
CA2261974A1 (en) | 1996-07-25 | 1998-02-05 | Biogen, Inc. | Molecular model for vla-4 inhibitors |
DE19647381A1 (de) * | 1996-11-15 | 1998-05-20 | Hoechst Ag | Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten |
PL323130A1 (en) * | 1996-11-15 | 1998-05-25 | Hoechst Ag | Application of heterocyclic compounds in production of a pharmaceutic agent, novel heterocyclic compounds and pharmaceutic agent as such |
DE19647380A1 (de) * | 1996-11-15 | 1998-05-20 | Hoechst Ag | 5-Ring-Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten |
US6642261B2 (en) | 1997-11-21 | 2003-11-04 | Athena Neurosciences, Inc. | N-(aryl/heteroarylacety) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
US6117901A (en) | 1996-11-22 | 2000-09-12 | Athena Neurosciences, Inc. | N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for use |
US6096782A (en) * | 1996-11-22 | 2000-08-01 | Athena Neurosciences, Inc. | N-(aryl/heteroaryl) amino acid derivatives pharmaceutical compositions comprising same and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
US6207710B1 (en) | 1996-11-22 | 2001-03-27 | Elan Pharmaceuticals, Inc. | Compounds for inhibiting β-amyloid peptide release and/or its synthesis |
US6211235B1 (en) | 1996-11-22 | 2001-04-03 | Elan Pharmaceuticals, Inc. | Compounds for inhibiting β-amyloid peptide release and/or its synthesis |
US6191166B1 (en) | 1997-11-21 | 2001-02-20 | Elan Pharmaceuticals, Inc. | Methods and compounds for inhibiting β-amyloid peptide release and/or its synthesis |
US6635632B1 (en) | 1996-12-23 | 2003-10-21 | Athena Neurosciences, Inc. | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
US6683075B1 (en) | 1996-12-23 | 2004-01-27 | Athena Neurosciences, Inc. | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use |
ATE318841T1 (de) * | 1997-05-29 | 2006-03-15 | Merck & Co Inc | Biarylalkansäuren in der verwendung als zelladhäsionsinhibitoren |
US6291511B1 (en) | 1997-05-29 | 2001-09-18 | Merck & Co., Inc. | Biarylalkanoic acids as cell adhesion inhibitors |
US6903075B1 (en) | 1997-05-29 | 2005-06-07 | Merck & Co., Inc. | Heterocyclic amide compounds as cell adhesion inhibitors |
CA2291708A1 (en) * | 1997-05-29 | 1998-12-03 | Merck & Co., Inc. | Sulfonamides as cell adhesion inhibitors |
US6221888B1 (en) | 1997-05-29 | 2001-04-24 | Merck & Co., Inc. | Sulfonamides as cell adhesion inhibitors |
WO1998054207A1 (en) * | 1997-05-30 | 1998-12-03 | Celltech Therapeutics Limited | Anti-inflammatory tyrosine derivatives |
JP2001517246A (ja) * | 1997-06-23 | 2001-10-02 | 田辺製薬株式会社 | α▲下4▼β▲下1▼媒介細胞接着の阻止剤 |
CA2291475A1 (en) * | 1997-07-31 | 1999-02-11 | Elan Pharmaceuticals, Inc. | Dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4 |
US6559127B1 (en) | 1997-07-31 | 2003-05-06 | Athena Neurosciences, Inc. | Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
US6492421B1 (en) | 1997-07-31 | 2002-12-10 | Athena Neurosciences, Inc. | Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4 |
AU8823498A (en) * | 1997-07-31 | 1999-02-22 | American Home Products Corporation | Sulfonylated dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4 |
AR013384A1 (es) * | 1997-07-31 | 2000-12-27 | Athena Neurosciences Inc | Compuestos del tipo de fenilalanina substituidos que inhiben la adhesion de leucocitos intermediada por vla-4 |
US6423688B1 (en) | 1997-07-31 | 2002-07-23 | Athena Neurosciences, Inc. | Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4 |
US6583139B1 (en) | 1997-07-31 | 2003-06-24 | Eugene D. Thorsett | Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
WO1999006436A1 (en) * | 1997-07-31 | 1999-02-11 | Elan Pharmaceuticals, Inc. | Benzyl compounds which inhibit leukocyte adhesion mediated by vla-4 |
US7030114B1 (en) | 1997-07-31 | 2006-04-18 | Elan Pharmaceuticals, Inc. | Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
IL133641A0 (en) * | 1997-07-31 | 2001-04-30 | Elan Pharm Inc | Compounds which inhibit leukocyte adhesion mediated by vla-4 |
PL338373A1 (en) * | 1997-07-31 | 2000-10-23 | Elan Pharm Inc | Dipeptide and its affinite compounds inhibiting adhesion of leucocytes occurring through mediation of vla-4 |
CA2290750A1 (en) * | 1997-07-31 | 1999-02-11 | Elan Pharmaceuticals, Inc. | 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4 |
US6489300B1 (en) | 1997-07-31 | 2002-12-03 | Eugene D. Thorsett | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 |
US6362341B1 (en) | 1997-07-31 | 2002-03-26 | Athena Neurosciences, Inc. | Benzyl compounds which inhibit leukocyte adhesion mediated by VLA-4 |
US6939855B2 (en) * | 1997-07-31 | 2005-09-06 | Elan Pharmaceuticals, Inc. | Anti-inflammatory compositions and method |
US6291453B1 (en) | 1997-07-31 | 2001-09-18 | Athena Neurosciences, Inc. | 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4 |
US6455550B1 (en) | 1997-08-22 | 2002-09-24 | Hoffmann-La Roche Inc. | N-alkanoylphenylalanine derivatives |
EP1403247A1 (en) * | 1997-08-22 | 2004-03-31 | F.Hoffmann-La Roche Ag | N-Alkanoylphenylalanine derivatives |
US6229011B1 (en) | 1997-08-22 | 2001-05-08 | Hoffman-La Roche Inc. | N-aroylphenylalanine derivative VCAM-1 inhibitors |
PL193283B1 (pl) * | 1997-08-22 | 2007-01-31 | Hoffmann La Roche | Nowe pochodne N-aroilofenyloalaniny, ich zastosowanie i środek leczniczy |
DE19741235A1 (de) | 1997-09-18 | 1999-03-25 | Hoechst Marion Roussel De Gmbh | Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
DE19741873A1 (de) * | 1997-09-23 | 1999-03-25 | Hoechst Marion Roussel De Gmbh | Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
US6069163A (en) * | 1997-10-21 | 2000-05-30 | Merck & Co., Inc. | Azapeptide acids as cell adhesion inhibitors |
IL135836A0 (en) * | 1997-10-31 | 2001-05-20 | Aventis Pharma Ltd | Substituted anilides |
GB9723789D0 (en) * | 1997-11-12 | 1998-01-07 | Zeneca Ltd | Chemical compounds |
US6020347A (en) * | 1997-11-18 | 2000-02-01 | Merck & Co., Inc. | 4-substituted-4-piperidine carboxamide derivatives |
DE19751251A1 (de) | 1997-11-19 | 1999-05-20 | Hoechst Marion Roussel De Gmbh | Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate |
US6191171B1 (en) | 1997-11-20 | 2001-02-20 | Merck & Co., Inc. | Para-aminomethylaryl carboxamide derivatives |
US6090841A (en) * | 1997-11-21 | 2000-07-18 | Merck & Co., Inc. | Substituted pyrrole derivatives as cell adhesion inhibitors |
DE69824037T2 (de) * | 1997-11-24 | 2005-06-02 | Merck & Co., Inc. | Beta-alanin-derivate als zell-adhäsions-inhibitoren |
US6645939B1 (en) | 1997-11-24 | 2003-11-11 | Merck & Co., Inc. | Substituted β-alanine derivatives as cell adhesion inhibitors |
US6423689B1 (en) | 1997-12-22 | 2002-07-23 | Warner-Lambert Company | Peptidyl calcium channel blockers |
JP4555469B2 (ja) * | 1997-12-23 | 2010-09-29 | アベンテイス・フアルマ・リミテツド | 置換されたβ−アラニン |
US6100282A (en) | 1998-01-02 | 2000-08-08 | Hoffman-La Roche Inc. | Thiazole derivatives |
EP0928790B1 (en) * | 1998-01-02 | 2003-03-05 | F. Hoffmann-La Roche Ag | Thiazole derivatives |
US6197794B1 (en) * | 1998-01-08 | 2001-03-06 | Celltech Therapeutics Limited | Phenylalanine derivatives |
MY153569A (en) | 1998-01-20 | 2015-02-27 | Mitsubishi Tanabe Pharma Corp | Inhibitors of ?4 mediated cell adhesion |
US6407065B1 (en) | 1998-01-23 | 2002-06-18 | Novartis Ag | VLA-4 antagonists |
IL137329A0 (en) * | 1998-01-23 | 2001-07-24 | Novartis Ag | Vla-4 antagonists |
US6329372B1 (en) | 1998-01-27 | 2001-12-11 | Celltech Therapeutics Limited | Phenylalanine derivatives |
GB9805655D0 (en) | 1998-03-16 | 1998-05-13 | Celltech Therapeutics Ltd | Chemical compounds |
US6521626B1 (en) | 1998-03-24 | 2003-02-18 | Celltech R&D Limited | Thiocarboxamide derivatives |
PL346220A1 (en) | 1998-04-16 | 2002-01-28 | Texas Biotechnology Corp | Compounds that inhibit the binding of integrins to their receptors |
DE19821483A1 (de) | 1998-05-14 | 1999-11-18 | Hoechst Marion Roussel De Gmbh | Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
GB9811159D0 (en) | 1998-05-22 | 1998-07-22 | Celltech Therapeutics Ltd | Chemical compounds |
CN1148350C (zh) * | 1998-05-28 | 2004-05-05 | 拜奥根有限公司 | 新型VLA-4抑制剂:oMePUPA-V |
GB9811969D0 (en) | 1998-06-03 | 1998-07-29 | Celltech Therapeutics Ltd | Chemical compounds |
US6528505B1 (en) | 1998-06-22 | 2003-03-04 | Elan Pharmaceuticals, Inc. | Cyclic amino acid compounds pharmaceutical compositions comprising same and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
US6774125B2 (en) | 1998-06-22 | 2004-08-10 | Elan Pharmaceuticals, Inc. | Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
US6569851B1 (en) | 1998-06-22 | 2003-05-27 | Elan Pharmaceutials, Inc. | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
US6552013B1 (en) | 1998-06-22 | 2003-04-22 | Elan Pharmaceuticals, Inc. | Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
US6509331B1 (en) | 1998-06-22 | 2003-01-21 | Elan Pharmaceuticals, Inc. | Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
US6958330B1 (en) | 1998-06-22 | 2005-10-25 | Elan Pharmaceuticals, Inc. | Polycyclic α-amino-ε-caprolactams and related compounds |
TW591026B (en) * | 1998-06-23 | 2004-06-11 | Upjohn Co | Inhibitors of alpha4beta1 mediated cell adhesion |
US6685617B1 (en) | 1998-06-23 | 2004-02-03 | Pharmacia & Upjohn Company | Inhibitors of α4β1 mediated cell adhesion |
IL139584A0 (en) * | 1998-06-30 | 2002-02-10 | Pfizer Prod Inc | Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory autoimmune and respiratory diseases |
GB9814414D0 (en) | 1998-07-03 | 1998-09-02 | Celltech Therapeutics Ltd | Chemical compounds |
US6352977B1 (en) | 1998-07-13 | 2002-03-05 | Aventis Pharma Limited | Substituted β-alanines |
GB9916374D0 (en) * | 1998-07-23 | 1999-09-15 | Zeneca Ltd | Chemical compounds |
AU5052199A (en) * | 1998-07-23 | 2000-02-14 | Astrazeneca Ab | Chemical compounds |
GB9821061D0 (en) | 1998-09-28 | 1998-11-18 | Celltech Therapeutics Ltd | Chemical compounds |
GB9821222D0 (en) | 1998-09-30 | 1998-11-25 | Celltech Therapeutics Ltd | Chemical compounds |
AU760219B2 (en) * | 1998-10-22 | 2003-05-08 | F. Hoffmann-La Roche Ag | Thiazole-derivatives |
GB9825652D0 (en) | 1998-11-23 | 1999-01-13 | Celltech Therapeutics Ltd | Chemical compounds |
GB9826174D0 (en) | 1998-11-30 | 1999-01-20 | Celltech Therapeutics Ltd | Chemical compounds |
DE69915692T2 (de) * | 1998-12-22 | 2005-02-10 | Tanabe Seiyaku Co., Ltd. | Inhibitoren der alpha-4 beta-1 vermittelten zelladhäsion |
ES2339738T3 (es) | 1999-01-22 | 2010-05-25 | Elan Pharmaceuticals, Inc. | Derivados de acilo los cuales tratan trastornos relacionados con vla-4. |
AR035476A1 (es) | 1999-01-22 | 2004-06-02 | Elan Pharm Inc | Compuestos heteroarilo y heterociclicos con anillo fusionado, los cuales inhiben la adhesion de leucocitos mediada por vla-4, composiciones farmaceuticas, el uso de las mismas para la manufactura de un medicamento y un metodo para fijar vla-4 en una muestra biologica |
US6436904B1 (en) | 1999-01-25 | 2002-08-20 | Elan Pharmaceuticals, Inc. | Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
JP2002539080A (ja) * | 1999-01-25 | 2002-11-19 | エラン ファーマシューティカルズ,インコーポレイテッド | Vla−4によって媒介される白血球接着を阻害する化合物 |
US6407066B1 (en) | 1999-01-26 | 2002-06-18 | Elan Pharmaceuticals, Inc. | Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4 |
PT1153017E (pt) | 1999-02-16 | 2006-07-31 | Aventis Pharma Ltd | Compostos biciclicos e sua utilizacao como ligandos do receptor de integrina |
IL144641A0 (en) | 1999-02-18 | 2002-05-23 | Hoffmann La Roche | Phenylalaninol derivatives |
NZ513254A (en) | 1999-02-18 | 2003-10-31 | F | Thioamide derivatives |
ES2251360T3 (es) * | 1999-03-12 | 2006-05-01 | Boehringer Ingelheim Pharmaceuticals Inc. | Compuestos heterociclicos aromaticos en calidad de agentes antiinflamatorios. |
GB9909409D0 (en) * | 1999-04-24 | 1999-06-23 | Zeneca Ltd | Chemical compounds |
US6723711B2 (en) | 1999-05-07 | 2004-04-20 | Texas Biotechnology Corporation | Propanoic acid derivatives that inhibit the binding of integrins to their receptors |
AU5267900A (en) * | 1999-05-07 | 2000-11-21 | Texas Biotechnology Corporation | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors |
US6972296B2 (en) | 1999-05-07 | 2005-12-06 | Encysive Pharmaceuticals Inc. | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors |
US6518283B1 (en) | 1999-05-28 | 2003-02-11 | Celltech R&D Limited | Squaric acid derivatives |
US6756378B2 (en) | 1999-06-30 | 2004-06-29 | Pharmacopeia Drug Discovery, Inc. | VLA-4 inhibitor compounds |
AR035011A1 (es) * | 1999-06-30 | 2004-04-14 | Daiichi Seiyaku Co | Compuestos inhibidores de vla-4 |
AU6314200A (en) * | 1999-07-26 | 2001-02-13 | Toray Industries, Inc. | Carboxylic acid derivatives and adhesion molecule inhibitors containing the sameas the active ingredient |
GEP20063956B (en) * | 1999-08-13 | 2006-11-10 | Biogen Idec Inc | Cell adhesion inhibitors |
US6534513B1 (en) | 1999-09-29 | 2003-03-18 | Celltech R&D Limited | Phenylalkanoic acid derivatives |
US6849639B2 (en) * | 1999-12-14 | 2005-02-01 | Amgen Inc. | Integrin inhibitors and their methods of use |
EP2140881B1 (en) | 1999-12-16 | 2013-04-17 | Biogen Idec MA Inc. | Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists |
US6455539B2 (en) | 1999-12-23 | 2002-09-24 | Celltech R&D Limited | Squaric acid derivates |
AU2284001A (en) * | 1999-12-27 | 2001-07-09 | Ortho-Mcneil Pharmaceutical, Inc. | Substituted aminoalkylamide derivatives as antagonists of follicle stimulating hormone |
AP2002002565A0 (en) | 1999-12-28 | 2002-06-30 | Pfizer Prod Inc | Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases. |
WO2001079173A2 (en) | 2000-04-17 | 2001-10-25 | Celltech R & D Limited | Enamine derivatives as cell adhesion molecules |
DE10019755A1 (de) * | 2000-04-20 | 2001-11-08 | Bayer Ag | Neue Aminoaryl/cycloalkylcarbonsäuren als Integrinantagonisten |
IL152450A0 (en) * | 2000-05-12 | 2003-05-29 | Genzyme Corp | COMPOUNDS HAVING TNF-alpha SIGNAL MODULATING ACTIVITY |
US6545013B2 (en) | 2000-05-30 | 2003-04-08 | Celltech R&D Limited | 2,7-naphthyridine derivatives |
US6403608B1 (en) | 2000-05-30 | 2002-06-11 | Celltech R&D, Ltd. | 3-Substituted isoquinolin-1-yl derivatives |
WO2002004426A1 (en) | 2000-07-07 | 2002-01-17 | Celltech R & D Limited | Squaric acid derivatives containing a bicyclic heteroaromatic ring as integrin antagonists |
EP1305291A1 (en) | 2000-08-02 | 2003-05-02 | Celltech R&D Limited | 3-substituted isoquinolin-1-yl derivatives |
WO2002016329A1 (fr) | 2000-08-18 | 2002-02-28 | Ajinomoto Co., Inc. | Nouveaux derives de phenylalanine |
MY129000A (en) | 2000-08-31 | 2007-03-30 | Tanabe Seiyaku Co | INHIBITORS OF a4 MEDIATED CELL ADHESION |
DE10063173A1 (de) * | 2000-12-18 | 2002-06-20 | Merck Patent Gmbh | Harnstoff- und Urethanderivate |
AU2002241724A1 (en) | 2000-12-20 | 2002-07-01 | Bristol-Myers Squibb Company | Diamines as modulators of chemokine receptor activity |
AR035773A1 (es) | 2000-12-20 | 2004-07-14 | Bristol Myers Squibb Pharma Co | Compuestos diamino ciclico, composicion farmaceutica y su uso en la fabricacion de un medicamento util para modular la actividad de una quimioquina |
KR100884877B1 (ko) | 2000-12-28 | 2009-02-23 | 다이이찌 세이야꾸 가부시기가이샤 | Vla-4 저해제 |
DE10105077A1 (de) * | 2001-02-05 | 2002-08-08 | Febit Ferrarius Biotech Gmbh | Hybrid-Schutzgruppe |
DE10111877A1 (de) | 2001-03-10 | 2002-09-12 | Aventis Pharma Gmbh | Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
DE10112771A1 (de) * | 2001-03-16 | 2002-09-26 | Merck Patent Gmbh | Inhibitoren des Integrins alpha¶v¶beta¶6¶ |
DE10127041A1 (de) * | 2001-06-02 | 2002-12-05 | Merck Patent Gmbh | Integrinantagonisten |
US6844028B2 (en) | 2001-06-26 | 2005-01-18 | Accelr8 Technology Corporation | Functional surface coating |
US7501157B2 (en) | 2001-06-26 | 2009-03-10 | Accelr8 Technology Corporation | Hydroxyl functional surface coating |
GB2377933A (en) | 2001-07-06 | 2003-01-29 | Bayer Ag | Succinic acid derivatives useful as integrin antagonists |
DE10137595A1 (de) | 2001-08-01 | 2003-02-13 | Aventis Pharma Gmbh | Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung |
AU2002356180A1 (en) * | 2001-08-06 | 2003-03-10 | The Regents Of The University Of California | Methods for inhibiting angiogenesis |
US20040191926A1 (en) * | 2001-09-26 | 2004-09-30 | Zhong-Yin Zhang | Ptp1b inhibitors and ligands |
EP1297830A1 (en) * | 2001-09-28 | 2003-04-02 | Flamma Fabbrica Lombarda Ammino Acidi S.p.a. | Use of alpha- or beta-amino acids, of the corresponding esters or of dipeptides of these amino acids with histidine derivatives in the prevention or treatment of tissue damage caused by a atmospheric ozone |
DE10154280A1 (de) * | 2001-11-05 | 2003-05-15 | Wilex Ag | Antagonisten für alpha¶4¶-Integrine |
AR038136A1 (es) | 2002-01-24 | 2004-12-29 | Merck Frosst Canada Inc | Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento |
DE10204789A1 (de) * | 2002-02-06 | 2003-08-14 | Merck Patent Gmbh | Inhibitoren des Integrins alpha¶v¶beta6 |
MY140707A (en) * | 2002-02-28 | 2010-01-15 | Mitsubishi Tanabe Pharma Corp | Process for preparing a phenylalanine derivative and intermediates thereof |
TWI281470B (en) | 2002-05-24 | 2007-05-21 | Elan Pharm Inc | Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins |
TW200307671A (en) | 2002-05-24 | 2003-12-16 | Elan Pharm Inc | Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins |
CN1703395A (zh) * | 2002-08-09 | 2005-11-30 | 特兰斯泰克制药公司 | 芳基和杂芳基化合物以及调节凝血的方法 |
WO2004041279A1 (en) | 2002-10-30 | 2004-05-21 | Merck & Co., Inc. | Gamma-aminoamide modulators of chemokine receptor activity |
PT1567138E (pt) * | 2002-11-21 | 2011-04-11 | Genzyme Corp | Utilização de derivados de diamida para inibição de rejeição crónica de transplante |
AU2003291143A1 (en) * | 2002-11-21 | 2004-06-18 | Genzyme Corporation | Combination of diamide derivatives and immunosuppressive agents for induction of immune tolerance |
JP2007526230A (ja) * | 2003-06-25 | 2007-09-13 | エラン ファーマシューティカルズ,インコーポレイテッド | 関節リウマチを治療する方法および組成物 |
US7626985B2 (en) * | 2003-06-27 | 2009-12-01 | Broadcom Corporation | Datagram replication in internet protocol multicast switching in a network device |
CN1826336B (zh) | 2003-07-24 | 2010-06-02 | 第一制药株式会社 | 环己烷羧酸类 |
US7208601B2 (en) * | 2003-08-08 | 2007-04-24 | Mjalli Adnan M M | Aryl and heteroaryl compounds, compositions, and methods of use |
WO2005014532A1 (en) * | 2003-08-08 | 2005-02-17 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions and methods of use |
EP1685236A4 (en) | 2003-09-29 | 2008-01-23 | Univ California | METHOD FOR CHANGING ADHESION, DIFFERENTIATION AND MIGRATION OF HEMATOPOIDIC PRECURSOR CELLS |
US20050209232A1 (en) * | 2004-02-10 | 2005-09-22 | Kent Barbay | Pyridazinone ureas as antagonists of alpha4 integrins |
JP2007522225A (ja) * | 2004-02-10 | 2007-08-09 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | A4インテグリン拮抗薬としてのピリダジノン |
US7419666B1 (en) | 2004-02-23 | 2008-09-02 | Massachusetts Eye And Ear Infirmary | Treatment of ocular disorders |
US20050234261A1 (en) * | 2004-04-14 | 2005-10-20 | Honeywell International Inc. | Process for preparing cinnamic acids and alkyl esters thereof |
WO2005114197A2 (en) * | 2004-04-15 | 2005-12-01 | Albert Einstein College Of Medicine Of Yeshiva University | Activity-based probes for protein tyrosine phosphatases |
US7196112B2 (en) | 2004-07-16 | 2007-03-27 | Biogen Idec Ma Inc. | Cell adhesion inhibitors |
PE20100809A1 (es) * | 2005-07-11 | 2011-01-07 | Wyeth Llc | Inhibidores de glutamato de metaloproteinasas de matriz y agrecanasas |
CA2624450C (en) | 2005-09-29 | 2014-02-04 | Elan Pharmaceuticals, Inc. | Pyrimidinyl amide compounds which inhibit leukocyte adhesion mediated by vla-4 |
BRPI0616643A2 (pt) | 2005-09-29 | 2011-06-28 | Elan Pharm Inc | compostos de carbamato que inibem a adesão leucocitária mediada por vla-4 |
GT200600305A (es) * | 2005-10-13 | 2007-02-26 | Métodos para preparar derivados de acido glutamico | |
WO2007092471A2 (en) | 2006-02-03 | 2007-08-16 | The Regents Of The University Of California | Methods for inhibition of lymphangiogenesis and tumor metastasis |
BRPI0708331A2 (pt) | 2006-02-27 | 2011-05-24 | Elan Pharm Inc | compostos de pirimidinil sulfonamida que inibem a adesão leucocitária mediada por vla-4 |
EP2124996A4 (en) | 2007-02-20 | 2010-03-24 | Merrimack Pharmaceuticals Inc | METHODS OF TREATING MULTIPLE SCLEROSIS BY ADMINISTERING ALPHA-FETOPROTEIN COMBINED WITH INTEGRIN ANTAGONIST |
WO2009076434A1 (en) * | 2007-12-12 | 2009-06-18 | Molecular Insight Pharmaceuticals, Inc. | Inhibitors of integrin vla-4 |
EP2288715B1 (en) | 2008-04-11 | 2014-09-24 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
CA2737483A1 (en) | 2008-09-22 | 2010-03-25 | Merck Frosst Canada Ltd. | Indole derivatives as crth2 receptor antagonists |
WO2010059315A1 (en) | 2008-11-18 | 2010-05-27 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
MX2011005526A (es) | 2008-11-26 | 2011-06-06 | Pfizer | 3-aminociclopentancarboxamidas como moduladores de receptores de quimiocina. |
SG172857A1 (en) | 2009-02-09 | 2011-08-29 | Supergen Inc | Pyrrolopyrimidinyl axl kinase inhibitors |
RS53268B (en) | 2009-02-24 | 2014-08-29 | Merck Canada Inc. | INDOLE DERIVATIVES AS AN ANTAGONISTS OF CRTH2 RECEPTORS |
CA2760151A1 (en) | 2009-04-27 | 2010-11-04 | Elan Pharmaceuticals, Inc. | Pyridinone antagonists of alpha-4 integrins |
EP2467159A1 (en) | 2009-08-20 | 2012-06-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy |
US8703877B2 (en) * | 2009-11-11 | 2014-04-22 | 3M Innovative Properties Company | Polymeric compositions and method of making and articles thereof |
GB0922014D0 (en) * | 2009-12-17 | 2010-02-03 | Ge Healthcare Ltd | Novel integrin binders |
WO2012051036A1 (en) | 2010-10-11 | 2012-04-19 | Merck Sharp & Dohme Corp. | Quinazolinone-type compounds as crth2 antagonists |
KR20130133219A (ko) | 2010-12-23 | 2013-12-06 | 머크 샤프 앤드 돔 코포레이션 | Crth₂ 수용체 조절제로서의 퀴녹살린 및 아자-퀴녹살린 |
WO2012151137A1 (en) | 2011-05-04 | 2012-11-08 | Merck Sharp & Dohme Corp. | Amino-pyridine-containing spleen tyrosine kinase (syk) inhibitors |
CN103763924B (zh) | 2011-06-17 | 2016-05-18 | 默沙东公司 | 作为crth2受体调节剂的环烷基稠合的四氢喹啉 |
EP2763975B1 (en) | 2011-10-05 | 2016-04-06 | Merck Sharp & Dohme Corp. | 3-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors |
CA2848587A1 (en) | 2011-10-17 | 2013-04-25 | Westfaelische Wilhelms-Universitaet Muenster | Methods of risk assessment of pml and related apparatus |
WO2013158597A1 (en) * | 2012-04-16 | 2013-10-24 | Allergan, Inc. | (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators |
US9345766B2 (en) | 2012-08-30 | 2016-05-24 | Merrimack Pharmaceuticals, Inc. | Combination therapies comprising anti-ERBB3 agents |
JP2017510627A (ja) | 2014-03-13 | 2017-04-13 | プロセナ バイオサイエンシーズ リミテッド | 多発性硬化症の併用治療 |
WO2018140510A1 (en) | 2017-01-25 | 2018-08-02 | Biogen Ma Inc. | Compositions and methods for treatment of stroke and other cns disorders |
US10875875B2 (en) | 2017-04-26 | 2020-12-29 | Aviara Pharmaceuticals, Inc. | Propionic acid derivatives and methods of use thereof |
MA50173A (fr) | 2017-09-13 | 2020-07-29 | Amgen Inc | Composés activateurs de bisamide sarcomère et leurs utilisations |
US20190330141A1 (en) * | 2018-04-30 | 2019-10-31 | The Procter & Gamble Company | Compositions With A Cooling Effect |
JP2022517610A (ja) | 2019-01-10 | 2022-03-09 | シーエスピーシー ゾンチー ファーマシューティカル テクノロジー(シージアチュアン)カンパニー,リミテッド | 複素環化合物塩およびその使用 |
WO2022162164A1 (en) | 2021-01-29 | 2022-08-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of assessing the risk of developing progressive multifocal leukoencephalopathy in patients treated with vla-4 antagonists |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4725583A (en) * | 1985-01-23 | 1988-02-16 | Abbott Laboratories | Functionalized peptidylaminoalcohols |
US4826815A (en) * | 1985-05-17 | 1989-05-02 | Abbott Laboratories | Renin inhibiting compounds |
CA2043741C (en) | 1990-06-07 | 2003-04-01 | Kiyofumi Ishikawa | Endothelin antagonistic peptide derivatives |
US5192746A (en) | 1990-07-09 | 1993-03-09 | Tanabe Seiyaku Co., Ltd. | Cyclic cell adhesion modulation compounds |
US5260277A (en) | 1990-09-10 | 1993-11-09 | Tanabe Seiyaku Co., Ltd. | Guanidinyl and related cell adhesion modulation compounds |
WO1992008464A1 (en) | 1990-11-15 | 1992-05-29 | Tanabe Seiyaku Co. Ltd. | Substituted urea and related cell adhesion modulation compounds |
CA2071674C (en) | 1991-06-21 | 2003-08-19 | Kevin T. Chapman | Peptidyl derivatives as inhibitors of interleukin-1.beta. converting enzyme |
WO1993008823A1 (en) | 1991-11-06 | 1993-05-13 | Tanabe Seiyaku Co., Ltd. | Guanidinyl and related cell adhesion modulation compounds |
DE69222433D1 (de) | 1991-11-22 | 1997-10-30 | Yeda Res & Dev | Nicht-peptidische surrogate der arg-gly-asp sequenz und entsprechende pharmazeutische zusammensetzungen |
WO1993012809A1 (en) * | 1991-12-24 | 1993-07-08 | Fred Hutchinson Cancer Research Center | Competitive inhibition of high-avidity alpha4-beta1 receptor using tripeptide ldv |
DE4212304A1 (de) | 1992-04-13 | 1993-10-14 | Cassella Ag | Asparaginsäurederivate, ihre Herstellung und Verwendung |
IL102646A (en) | 1992-07-26 | 1996-05-14 | Yeda Res & Dev | Non-peptidic surrogates of the ldv sequence and pharmaceutical compositions comprising them |
WO1994015958A2 (en) | 1993-01-08 | 1994-07-21 | Tanabe Seiyaku Co., Ltd. | Peptide inhibitors of cell adhesion |
US5314902A (en) * | 1993-01-27 | 1994-05-24 | Monsanto Company | Urea derivatives useful as platelet aggregation inhibitors |
US6268380B1 (en) * | 1993-02-19 | 2001-07-31 | G. D. Searle & Co. | Urea derivatives useful as platelet aggregation inhibitors |
WO1994023714A1 (en) | 1993-04-09 | 1994-10-27 | Toyama Chemical Co., Ltd. | Immunomodulator, cell adhesion inhibitor, and agent for treating and preventing autoimmune diseases |
IT1270882B (it) * | 1993-10-05 | 1997-05-13 | Isagro Srl | Oligopeptidi ad attivita' fungicida |
AU693143B2 (en) | 1993-12-06 | 1998-06-25 | Cytel Corporation | CS-1 peptidomimetics, compositions and methods of using the same |
US5434188A (en) | 1994-03-07 | 1995-07-18 | Warner-Lambert Company | 1-ether and 1-thioether-naphthalene-2-carboxamides as inhibitors of cell adhesion and as inhibitors of the activation of HIV |
IT1271026B (it) * | 1994-10-21 | 1997-05-26 | Isagro Ricerca Srl | Derivati dell'acido b-amminopropionico ad attivita' fungicida |
US7001921B1 (en) * | 1995-01-23 | 2006-02-21 | Biogen Idec Ma Inc. | Cell adhesion inhibitors |
US6306840B1 (en) * | 1995-01-23 | 2001-10-23 | Biogen, Inc. | Cell adhesion inhibitors |
CA2261974A1 (en) * | 1996-07-25 | 1998-02-05 | Biogen, Inc. | Molecular model for vla-4 inhibitors |
-
1995
- 1995-01-23 US US08/376,372 patent/US6306840B1/en not_active Expired - Fee Related
-
1996
- 1996-01-18 KR KR1019970705068A patent/KR100413328B1/ko not_active IP Right Cessation
- 1996-01-18 NZ NZ336104A patent/NZ336104A/xx unknown
- 1996-01-18 RO RO97-01369A patent/RO119885B1/ro unknown
- 1996-01-18 AU AU49115/96A patent/AU718926B2/en not_active Ceased
- 1996-01-18 AT AT96905316T patent/ATE229498T1/de not_active IP Right Cessation
- 1996-01-18 ES ES96905316T patent/ES2183937T3/es not_active Expired - Lifetime
- 1996-01-18 DE DE69625332T patent/DE69625332T2/de not_active Expired - Fee Related
- 1996-01-18 BR BR9606778A patent/BR9606778A/pt not_active Application Discontinuation
- 1996-01-18 US US08/875,321 patent/US6376538B1/en not_active Expired - Fee Related
- 1996-01-18 HU HU9702461A patent/HU223350B1/hu not_active IP Right Cessation
- 1996-01-18 WO PCT/US1996/001349 patent/WO1996022966A1/en active IP Right Grant
- 1996-01-18 EP EP01107877A patent/EP1142867A2/en not_active Withdrawn
- 1996-01-18 CN CNB961922702A patent/CN1192015C/zh not_active Expired - Fee Related
- 1996-01-18 SK SK987-97A patent/SK283724B6/sk unknown
- 1996-01-18 JP JP52307196A patent/JP4129293B2/ja not_active Expired - Fee Related
- 1996-01-18 CZ CZ19972340A patent/CZ291556B6/cs not_active IP Right Cessation
- 1996-01-18 EA EA199700135A patent/EA003320B1/ru not_active IP Right Cessation
- 1996-01-18 EA EA200200844A patent/EA200200844A1/ru unknown
- 1996-01-18 PL PL96321848A patent/PL187313B1/pl not_active IP Right Cessation
- 1996-01-18 CA CA002211181A patent/CA2211181A1/en not_active Abandoned
- 1996-01-18 DK DK96905316T patent/DK0805796T3/da active
- 1996-01-18 EE EE9700172A patent/EE04111B1/xx not_active IP Right Cessation
- 1996-01-18 PT PT96905316T patent/PT805796E/pt unknown
- 1996-01-18 EP EP96905316A patent/EP0805796B1/en not_active Expired - Lifetime
- 1996-01-18 MX MX9705569A patent/MX9705569A/es not_active IP Right Cessation
- 1996-01-22 IL IL11684696A patent/IL116846A/en not_active IP Right Cessation
- 1996-01-22 TW TW085100690A patent/TW500714B/zh not_active IP Right Cessation
-
1997
- 1997-07-22 NO NO19973384A patent/NO320914B1/no unknown
- 1997-07-22 FI FI973087A patent/FI973087A/fi not_active Application Discontinuation
- 1997-08-21 BG BG101841A patent/BG63383B1/bg unknown
-
1998
- 1998-05-08 HK HK98104006A patent/HK1005241A1/xx not_active IP Right Cessation
-
2001
- 2001-08-22 US US09/935,461 patent/US6624152B2/en not_active Expired - Fee Related
- 2001-10-23 US US10/002,341 patent/US6630512B2/en not_active Expired - Fee Related
-
2002
- 2002-04-10 HK HK02102723.8A patent/HK1041477A1/zh unknown
-
2003
- 2003-10-07 US US10/679,478 patent/US20060166866A1/en not_active Abandoned
-
2007
- 2007-08-23 JP JP2007217671A patent/JP2008013574A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2183937T3 (es) | Inhibidores de la adhesion celular. | |
EA200100103A1 (ru) | Ингибиторы адгезии клеток | |
ES2181614T3 (es) | Sulfonilfenilheterociclos sustituidos como inhibidores de ciclooxigenasa-2 y 5-lipoxigenasa. | |
ECSP941104A (es) | Derivados de 2,6 diaminopurina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
CR7716A (es) | Uso de inhibidores de la ikb-quinasa para el tratamiento del dolor | |
ES2186015T3 (es) | Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol. | |
PA8462401A1 (es) | Derivados de la tienopirimidina y de la tienopiridina utiles como agentes anticancerigenos | |
SV1999000016A (es) | Derivados de 2-(purin-9-il-tetrahidrofuran-3,4-diol ref. pg3443/sv | |
GT200500007A (es) | [1,8]naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia. | |
HN1999000080A (es) | Derivados de isotiazol utiles como agentes anticancerosos. | |
AR023727A1 (es) | Compuestos empleados en el tratamiento de padecimientos inflamatorios | |
AR028948A1 (es) | Compuestos novedosos | |
ES2139959T3 (es) | Derivados de estilbeno utiles como inhibidores de la ciclooxigenasa-2. | |
BRPI0207961A8 (pt) | Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos. | |
UY26817A1 (es) | Agentes antiinflamatorios selectivos de glucocorticoides | |
DK1309589T3 (da) | Ureaforbindelser og anvendelsesfremgangsmåder | |
PA8583101A1 (es) | Nuevos compuestos de isotiazol e isoxazol como inhibidores del factor de crecimiento transformador (tgf) | |
PA8484301A1 (es) | Formulaciones farmaceuticas de liberacion controlada | |
IS8175A (is) | Píperasín afleiður og aðferðir við notkun þeirra | |
PA8582701A1 (es) | Nuevos compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformador (tgf) | |
UY27981A1 (es) | Nuevos compuestos de triazol como inhibidores del factor de crecimiento transformante (tgf) | |
AR021843A1 (es) | Derivados de propanolamina sustituidos con heterociclos, procedimiento para su preparacion, y su utilizacion. | |
BR0308184A (pt) | Composição oftálmica compreendendo ascomicina | |
ATE271861T1 (de) | Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen | |
MX9401295A (es) | Fosfonatos sustituidos, los procedimientos para supreparacion y composiciones farmaceuticas que los contienen. |